Longevity Today
Sign In

Results for "Personalized Longevity Medicine" in Diabetes

8 articles

All TopicsCancerHeart DiseaseAlzheimer'sParkinson'sDiabetesGut HealthNutritionStrength & FitnessSupplements & PeptidesStem CellsReversing AgingAuto-ImmunityAdvanced TherapiesSleep & Mindfulness
📋All Types🔬Papers📖Reviews▶️Videos🎙️Podcasts🧪Trials💊Approvals📰Press Releases📚Tutorials🎬Animations
FDA Fast-Tracks New Weight Loss Drug Foundayo Under Priority Program
Metabolic Health

FDA Fast-Tracks New Weight Loss Drug Foundayo Under Priority Program

Orforglipron approved 294 days ahead of schedule for obesity treatment, marking first drug under new priority voucher system.

Drug Approval
Apr 16, 2026 0
Orforglipron Oral GLP-1 Pill Approved as Obesity Pipeline Heats Up
Metabolic Health

Orforglipron Oral GLP-1 Pill Approved as Obesity Pipeline Heats Up

The FDA reportedly approved Eli Lilly's orforglipron, a daily oral GLP-1 receptor agonist for obesity, marking a potential shift from injectable weight-loss drugs.

Drug Approval
Apr 21, 2026 0
FDA Approves First Oral GLP-1 Weight Loss Pill Orforglipron
Metabolic Health

FDA Approves First Oral GLP-1 Weight Loss Pill Orforglipron

Foundayo (orforglipron) becomes the first oral GLP-1 receptor agonist approved for obesity, offering a pill alternative to injectable Wegovy.

Drug Approval
May 9, 2026 0
FDA Approves Foundayo for Weight Loss in Record 50 Days
Metabolic Health

FDA Approves Foundayo for Weight Loss in Record 50 Days

New GLP-1 drug Foundayo gets fastest FDA approval since 2002, targeting obesity and metabolic health through appetite control.

Drug Approval
Apr 6, 2026 0
FDA Approves Two New Weight Loss Drugs Foundayo and Zepbound for Obesity
Metabolic Health

FDA Approves Two New Weight Loss Drugs Foundayo and Zepbound for Obesity

FDA approves Foundayo (orforglipron) and Zepbound (tirzepatide) for chronic weight management in adults with obesity or overweight conditions.

Drug Approval
Apr 4, 2026 0
FDA Approves Two New Weight Loss Drugs in Record Two-Week Span
Metabolic Health

FDA Approves Two New Weight Loss Drugs in Record Two-Week Span

Foundayo and Zepbound receive rapid FDA approval for chronic weight management in adults with obesity or weight-related conditions.

Drug Approval
Apr 5, 2026 0
FDA Approves Utebzi for Complicated Urinary Tract Infections Including Pyelonephritis
Metabolic Health

FDA Approves Utebzi for Complicated Urinary Tract Infections Including Pyelonephritis

Tebipenem pivoxil becomes the first oral carbapenem approved in the US, offering a non-IV option for serious UTIs.

Drug Approval
Jun 21, 2026 0
FDA Approves Baxfendy, a New Aldosterone Synthase Inhibitor for Hypertension
Metabolic Health

FDA Approves Baxfendy, a New Aldosterone Synthase Inhibitor for Hypertension

Baxdrostat becomes the first-in-class aldosterone synthase inhibitor approved to treat resistant hypertension alongside existing drugs.

Drug Approval
May 19, 2026 0